Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1

Clinical Cancer Research

Volumn 11, Issue 9, 2005, Pages 3402-3409

  Plummer, E Ruth ^a,e   Middleton, Mark R ^b   Jones, Christopher ^a   Olsen, Anna ^c   Hickson, Ian ^c   McHugh, Peter ^c   Margison, Geoffrey P ^d   McGown, Gail ^d   Thorncroft, Mary ^d   Watson, Amanda J ^d   Boddy, Alan V ^a   Calvert, A Hilary ^a   Harris, Adrian L ^b   Newell, David R ^a   Curtin, Nicola J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 7 METHYLGUANINE; DACARBAZINE; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DNA DAMAGE; DNA METHYLATION; DNA STRAND BREAKAGE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BINDING; EXCISION REPAIR; FATIGUE; FEMALE; HEADACHE; HUMAN; INHIBITION KINETICS; MALE; MELANOMA; METASTASIS; NAUSEA; NEUTROPENIA; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR BIOPSY; VALIDATION PROCESS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; COMET ASSAY; DACARBAZINE; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DNA, NEOPLASM; FEMALE; HEADACHE; HUMANS; LYMPHOCYTES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLY(ADP-RIBOSE) POLYMERASES; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 20944447651     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2353     Document Type: Article

References (34)

1. DeVita VT, Hellman S, Rosenberg SA. Cancer principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997.
2. Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 2001; 1:13-9.
3. Newlands ES, Stevens MFG, Wedge SR. Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
4. 6-methylguanine. Mutagenesis 2002;17:483-7.
5. Karran P, Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv 1996;28: 69-85.
6. D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998;54:334-41.
7. Fink D, Aebi S, Howell S. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4:1-6.
8. Masson M, Niedergang C, Schreiber V, et al. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998;18:3563-71.
9. Burkle A. Physiology and pathophysiology of poly-(ADP-ribosyl)ation. Bioessays 2001;29:795-806.
10. de Murcia G, Menissier de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 1994;19:172-6.
11. Boulikas T. Relation between carcinogenesis, chromatin structure and poly(ADP-ribosylation) [review]. Anticancer Res 1991;11:489-527.
12. Mendoza-Alvarez H, Alvarez-Gonzalez R. Poly-(ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular. J Biol Chem 1993;268:22575-80.
13. Davidovic L, Vodenicharov M, Affar EB, Poirier GG. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp Cell Res 2001;268:7-13.
14. Southan GJ, Szabo C. Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 2003;10:321-40.
15. Boulton S, Pemberton LC, Porteous JK, et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 1995; 72:849-56.
16. Delaney CA, Wang LZ, Kyle S, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000;6:2860-7.
17. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003; 2:371-82.
18. Tentori L, Leonetti C, Scarsella M, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 2002;99:2241-4.
19. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
20. Shen F, Decosterd LA, Gander M, et al. Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Appl 1995; 667:291-300.
21. 7-methyldeoxyguanosine in DNA samples. Chem Res Toxicol 2001;14:295-301.
22. Olive PL, Chan APS, Cu CS. Comparison between the DNA precipitation and alkali unwinding assays for detecting DNA strand breaks and cross-links. Cancer Res 1988;48:6444-9.
23. Pfieffer R, Brabeck C, Burkle A. Quantitative nonisotopic immuno-dot-blot method for the assessment of cellular poly(ADP-ribosyl)ation capacity. Anal Biochem 1999;275:118-22.
24. Grube K, Kupper J, Burkle A. Direct stimulation of poly(ADP-ribose) polymerase in permeabilised cells by double-sttanded DNA oligomers. Anal Biochem 1991;193:236-9.
25. Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995;13:910-3.
26. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-66.
27. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65:287-91.
28. Braybrooke JP, Houlbrook S, Crawley JE, et al. Evaluation of the alkaline COMET assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. Cancer Chemother Pharmacol 2000; 45:111-9.
29. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994;69:452-6.
30. Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 1999; 20:199-203.
31. Shiobara M, Miyazaki M, Ito H, et al. Hepatocellular carcinoma: treatment and recurrence marker. J Gastroenterol Hepatol 2001;16:338-44.
32. Hirai K, Ueda K, Hayaishi O. Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers. Cancer Res 1983;43:3441-6.
33. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-7.
34. 6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998;78:1199-202.